{
  "symbol": "NVCT",
  "company_name": "Nuvectis Pharma Inc",
  "ir_website": "https://nuvectis.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer",
          "url": "https://nuvectis.com/press-release-view/?i=140268",
          "content": "[Skip to content](#primary)\n\n[ ![](https://i0.wp.com/nuvectis.com/wp-content/uploads/logo-nuvectis.png?fit=553%2C284&ssl=1) ](https://nuvectis.com)\n\n# Press Releases\n\n![](https://pixel.wp.com/g.gif?v=ext&blog=180844002&post=135&tz=-5&srv=nuvectis.com&j=1%3A14.0&host=nuvectis.com&ref=&fcp=0&rand=0.07834087827321401)\n"
        },
        {
          "title": "Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights",
          "url": "https://nuvectis.com/press-release-view/?i=139935",
          "content": "[Skip to content](#primary)\n\n[ ![](https://i0.wp.com/nuvectis.com/wp-content/uploads/logo-nuvectis.png?fit=553%2C284&ssl=1) ](https://nuvectis.com)\n\n# Press Releases\n\n![](https://pixel.wp.com/g.gif?v=ext&blog=180844002&post=135&tz=-5&srv=nuvectis.com&j=1%3A14.0&host=nuvectis.com&ref=&fcp=1999&rand=0.10694246483697833)\n"
        },
        {
          "title": "Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics",
          "url": "https://nuvectis.com/press-release-view/?i=139463",
          "content": "[Skip to content](#primary)\n\n[ ![](https://i0.wp.com/nuvectis.com/wp-content/uploads/logo-nuvectis.png?fit=553%2C284&ssl=1) ](https://nuvectis.com)\n\n# Press Releases\n\n![](https://pixel.wp.com/g.gif?v=ext&blog=180844002&post=135&tz=-5&srv=nuvectis.com&j=1%3A14.0&host=nuvectis.com&ref=&fcp=2256&rand=0.6321993604812437)\n"
        }
      ]
    }
  ]
}